Risk of cardiovascular disease in elderly subjects with obesity and liver fibrosis and the potential benefit of statin treatment
European Journal of Clinical Investigation · 2025
DOI: 10.1111/eci.14368 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Willy B Theel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Pravastatin, Obesity, Liver Cirrhosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb.
Abstract (Originalsprache)
Background
Liver fibrosis progression is influenced by older age and cardiometabolic risk factors such as obesity and is associated with an increased risk of cardiovascular events. While statins may protect against cardiovascular complications, their effects in elderly individuals with obesity and liver fibrosis are unclear.
Method
The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) database was used to evaluate the effect of pravastatin on major adverse cardiovascular events in an elderly population (>70 years). Subjects were categorized by BMI: lean (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal medicine, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands.
- Obesity Center CGG, Rotterdam, The Netherlands.
- Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
- Julius Clinical, Zeist, The Netherlands.
- Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Internal Medicine, Section of Gerontology & Geriatrics, Leiden University Medical Center, Leiden, The Netherlands.
ORCID-Profile: Willy B Theel
Förderung
- Bristol-Myers Squibb
Zitieren
APA
Theel, W. B., de Jong, V. D., Castro Cabezas, M., Grobbee, D. E., Jukema, J. W., & Trompet, S. (2025). Risk of cardiovascular disease in elderly subjects with obesity and liver fibrosis and the potential benefit of statin treatment. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14368
Vancouver
Theel WB, de Jong VD, Castro Cabezas M, Grobbee DE, Jukema JW, Trompet S. Risk of cardiovascular disease in elderly subjects with obesity and liver fibrosis and the potential benefit of statin treatment. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.14368
BibTeX
@article{Theel2025,
author = {Theel, Willy B and de Jong, Vivian D and Castro Cabezas, Manuel and Grobbee, Diederick E and Jukema, Johan W and Trompet, Stella},
title = {Risk of cardiovascular disease in elderly subjects with obesity and liver fibrosis and the potential benefit of statin treatment},
journal = {European Journal of Clinical Investigation},
year = {2025},
doi = {10.1111/eci.14368}
}
EUVIMED